Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tasly Pharmaceutical Group CoSHSE:600535 +1.46%79 Interest Coverage is 137.69 as of Mar. 2026, which is 1031% above its 10-year median of 12.17. GuruFocus rates SHSE:600535 with a GF Score™ of 79/100 and a GF Value™ of ¥15.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 74.96% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Tasly Pharmaceutical Group Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥458 Mil. Tasly Pharmaceutical Group Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-3 Mil.
Tasly Pharmaceutical Group Co's interest coverage for the quarter that ended in Mar. 2026 was 137.69.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Tasly Pharmaceutical Group Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's Interest Coverage or its related term are showing as below:
SHSE:600535'
s Interest Coverage Range Over the Past 10 Years
Min: 4.43 Med: 12.17 Max: 66.84
Current: 66.84
SHSE:600535's Interest Coverage is ranked better than 74.96% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs SHSE:600535: 66.84
Tasly Pharmaceutical Group Co (SHSE:600535) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Tasly Pharmaceutical Group Co Interest Coverage Related Terms
Tasly Pharmaceutical Group Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Tasly Pharmaceutical Group Co Interest Coverage Chart
SHSE:600535 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's Interest Coverage falls into.
Tasly Pharmaceutical Group Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a Interest Coverage of 137.69 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 1031% above median its historical median of 12.17. Over the past decade, Tasly Pharmaceutical Group Co's Interest Coverage has ranged from 4.43 to 66.84. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #172 out of 687 companies in the Drug Manufacturers industry, placing it in the top 25%.
Is Tasly Pharmaceutical Group Co's Interest Coverage too high?
Tasly Pharmaceutical Group Co's current Interest Coverage of 137.69 is 1031% above median its 10-year median of 12.17. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 66.84. The Drug Manufacturers industry median Interest Coverage is 12.75. Tasly Pharmaceutical Group Co's value of 137.69 is 979.9% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #172 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #172 out of 687 companies for Interest Coverage. This places Tasly Pharmaceutical Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Tasly Pharmaceutical Group Co's value of 137.69 is 979.9% above this benchmark. Historically, Tasly Pharmaceutical Group Co's own Interest Coverage has ranged from 4.43 to 66.84 over the past decade. While the company's 10-year median is 12.17 vs. the industry median of 12.75, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Interest Coverage of 137.69 is 979.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Interest Coverage is 137.69, which is 1031% above median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current Interest Coverage is 137.69, which is 1031% above median its 10-year median of 12.17 and 979.9% above the Drug Manufacturers industry median of 12.75. Tasly Pharmaceutical Group Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Interest Coverage is 137.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
Interest Coverage: 137.69 (1031% above median its 10-year median of 12.17)
GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
Industry Position: 979.9% above the Drug Manufacturers median (#172 of 687)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
79GF Score
Get the complete analysis for SHSE:600535
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
